Identification of the key genes and immune infiltrating cells determined by sex differences in ischaemic stroke through co-expression network module.
Haipeng XuYanzhi GeYang LiuYang ZhengRong HuConglin RenQianqian LiuPublished in: IET systems biology (2021)
Stroke is one of the leading causes of patients' death and long-term disability worldwide, and ischaemic stroke (IS) accounts for nearly 80% of all strokes. Differential genes and weighted gene co-expression network analysis (WGCNA) in male and female patients with IS were compared. The authors used cell type identification by estimating relative subsets of RNA transcripts (CIBERSORT) to analyse the distribution pattern of immune subtypes between male and female patients. In this study, 141 up-regulated and 61 down-regulated genes were gathered and distributed into five modules in response to their correlation degree to clinical traits. The criterion for Gene Ontology (GO) term and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway indicated that detailed analysis had the potential to enhance clinical prediction and to identify the gender-related mechanism. After that, the expression levels of hub genes were measured via the quantitative real-time PCR (qRT-PCR) method. Finally, CCL20, ICAM1 and PTGS2 were identified and these may be some promising targets for sex differences in IS. Besides, the hub genes were further verified by rat experiments. Furthermore, these CIBERSORT results showed that T cells CD8 and Monocytes may be the target for the treatment of male and female patients, respectively.
Keyphrases
- genome wide
- bioinformatics analysis
- network analysis
- end stage renal disease
- poor prognosis
- ejection fraction
- genome wide identification
- chronic kidney disease
- newly diagnosed
- prognostic factors
- peritoneal dialysis
- dna methylation
- magnetic resonance imaging
- long non coding rna
- genome wide analysis
- transcription factor
- induced apoptosis
- copy number
- computed tomography
- mass spectrometry
- endoplasmic reticulum stress
- atrial fibrillation
- combination therapy